Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Horizon therapeutics public limited company save search
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
Published: 2023-09-29 (Crawled : 23:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -0.05%
tepezza disease treatment thyroid eye
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.2%
H: 1.37%
C: 1.01%
rare disease therapeutics
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: 0.38%
tepezza disease active approved treatment thyroid brazil eye
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Published: 2023-05-01 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 0.5%
C: 0.46%
tepezza disease japan score thyroid eye trial therapeutics
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
Published: 2023-04-14 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
tepezza fda disease approval update thyroid eye therapeutics
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Published: 2023-04-10 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 0.72%
C: 0.28%
tepezza disease score positive thyroid topline eye trial therapeutics
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-11-16 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 1.08%
C: -0.54%
tepezza treatment thyroid disease active japan eye trial therapeutics
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -2.16%
H: 6.54%
C: 5.48%
tepezza thyroid disease meeting eye therapeutics
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Published: 2022-09-29 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.06%
H: 0.06%
C: -1.74%
tepezza thyroid disease eye trial therapeutics score
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.85%
H: 1.81%
C: -0.28%
thyroid disease eye therapeutics
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
Published: 2022-06-02 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -3.15%
H: 4.36%
C: 3.97%
conference disease education endocrine eye therapeutics
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
Published: 2022-05-11 (Crawled : 13:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 4.15%
H: 3.62%
C: -0.61%
disease eye therapeutics living
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.97%
H: 0.38%
C: -2.35%
treatment eye eye disease trial therapeutics disease active phase 3
Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
Published: 2022-02-15 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 1.72%
H: 1.0%
C: 0.02%
rare therapeutics disease children
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Published: 2021-12-16 (Crawled : 14:30) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: -4.22%
ALPN | $64.45 -0.02% -0.02% 2.5M
|
Health Technology
|
| O: 5.67%
H: 1.59%
C: -5.59%
license therapeutics disease collaboration
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Published: 2021-11-12 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
disease eye eye disease
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
Published: 2021-10-21 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.29%
H: 2.43%
C: 2.13%
disease eye eye disease
Winhealth-CARD Cooperation Boosts Rare Disease Healthy Ecosystem Construction
Published: 2021-10-08 (Crawled : 15:00) - prnewswire.com
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
disease rare
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis
Published: 2021-09-21 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.6%
H: 1.66%
C: 1.16%
disease genetic rare diagnostic
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.